Table 1

Summary of the endpoint results of the virtual patients in the simulations and CheckMate 040 for monotherapy of nivolumab (dose expansion phase, 3 mg/kg) and combination treatment of nivolumab and ipilimumab (arm A)

CheckMate 040SimulationsCheckMate 040Simulations
NivolumabCombination: arm A
No of patients2141365501365
Complete response, no (%)3 (1)23 (1.7)4 (8)16 (1.2)
Partial response, no (%)39 (18)242 (17.7)12 (24)299 (21.9)
Stable disease, no (%)96 (45)618 (45.3)9 (18)673 (49.3)
Progressive disease, no (%)68 (32)482 (35.3)20 (40)377 (27.6)
ORR % (95% CI)20 (15 to 26)19.4 (14.0 to 25.7)30.6 (21.8 to 48.9)23.1 (12 to 36)
  • ORR, objective response rate.